cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28433702.v1
title: Open label placebo for chronic low back pain: a systematic review and meta-analysis of randomized controlled trials

description: To assess the therapeutic potential of Open-Label Placebo (OLP) for chronic low back pain (CLBP). A systematic literature search was conducted on 12 September 2024. Data extraction focused on follow-up and change-from-baseline data of the placebo or control groups. The effect sizes were calculated using the inverse variance statistical method. A meta-analysis of four articles involving 171 OLP patients and 161 controls demonstrated a modest reduction in pain on the numerical rating scale (Mean difference = -0.62; 95% confidence interval: −1.09 to −0.14; <i>p</i> = 0.01; I<sup>2</sup> = 31%). However, according to GRADE, the certainty of evidence for this finding is very low due to methodological limitations of the included studies and potential biases. These findings, even if small, suggest potential benefits of OLP for pain reduction, with clinical relevance of the effect size being important depending on the clinical context and the patient’s perspective. OLP demonstrated a reduction in pain, with a slightly greater improvement observed during shorter intervention periods. However, the certainty of this evidence remains very low, indicating that these findings should be interpreted cautiously. Future clinical trials are needed to further explore the potential and limitations of this intervention. www.crd.york.ac.uk/prospero identifier is CRD42024568302. Chronic low back pain (CLBP) is a common and challenging condition to manage. Some recent studies have explored whether open-label placebos (OLPs) – placebos taken with full knowledge that they contain no active medicine – can help reduce pain and improve well-being. However, many of these studies have limitations, such as small sample sizes and potential biases, making it difficult to draw strong conclusions. Our review combined data from the available research to understand the potential effects of OLPs on CLBP. The findings suggest that OLPs may slightly reduce pain and improve symptoms like depression and disability. However, the overall certainty of the evidence is very low due to weaknesses in the included studies. While the results are promising, they should be interpreted with caution. More high-quality research is needed to confirm these findings and explore how OLPs might work over the long term. This review is an important step toward better understanding how OLPs could be used to manage chronic pain and improve patients’ lives.
DOI: 10.6084/m9.figshare.28524231.v2
title: Effectiveness and safety of anti-CGRP monoclonal antibodies for migraine in patients over 65 years: a systematic review

description: Migraine patients over 65 years have been excluded from pivotal anti-CGRP monoclonal antibody trials leaving limited real-life data on effectiveness and safety in this population. This review aims to summarize available evidence on treatment response and safety for older patients. A PubMed and Cochrane Controlled Register of Trials (CENTRAL) search identified studies on anti-CGRP monoclonal antibodies in patients with migraine over 65 up to October 2024. The review focuses on headache outcomes like reduction in monthly migraine days or monthly headache days, response rates (30%, 50%, 75%) and adverse effects of this specific population and/or against placebo, standard care, or younger patients. The quality of evidence was assessed using the GRADE tool. All eligible studies were included, along with additional articles presented narratively. Data from clinical trials and post-hoc analyses show comparable efficacy and safety between older and younger patients. Similarly, early real-life studies support the use of anti-CGRP monoclonal antibodies in patients over 65 years, showing similar response rates, reductions in monthly migraine days and adverse effects. Anti-CGRP monoclonal antibodies should likely be offered to patients over 65 although available evidence remains limited. Further studies analyzing specific data from this subgroup are necessary. Migraine in older adults can be more challenging to diagnose and treat due to changes in symptoms and the presence of other health conditions. These factors may limit treatment options. A new class of migraine treatments, called anti-CGRP monoclonal antibodies, has shown promising results in younger patients, but older adults were not included in key clinical trials. This review looks at the available research on how well these treatments work and how safe they are for people over 65. We analyzed studies that included older adults using these medications. The findings suggest that anti-CGRP monoclonal antibodies can reduce migraine frequency and severity in older patients, with effectiveness and side effects similar to those seen in younger adults, showing that they help patients who have not responded to other preventive treatments. However, the number of studies focusing on this age group is still limited. Overall, anti-CGRP monoclonal antibodies appear to be a good treatment option for older adults with migraine, provided they have no conditions that would make the treatment unsafe. However, more research is needed to better understand their long-term effects, particularly in patients with heart and blood vessel conditions, which are more common in this age group.
DOI: 10.6084/m9.figshare.28524231
title: Effectiveness and safety of anti-CGRP monoclonal antibodies for migraine in patients over 65 years: a systematic review

description: Migraine patients over 65 years have been excluded from pivotal anti-CGRP monoclonal antibody trials leaving limited real-life data on effectiveness and safety in this population. This review aims to summarize available evidence on treatment response and safety for older patients. A PubMed and Cochrane Controlled Register of Trials (CENTRAL) search identified studies on anti-CGRP monoclonal antibodies in patients with migraine over 65 up to October 2024. The review focuses on headache outcomes like reduction in monthly migraine days or monthly headache days, response rates (30%, 50%, 75%) and adverse effects of this specific population and/or against placebo, standard care, or younger patients. The quality of evidence was assessed using the GRADE tool. All eligible studies were included, along with additional articles presented narratively. Data from clinical trials and post-hoc analyses show comparable efficacy and safety between older and younger patients. Similarly, early real-life studies support the use of anti-CGRP monoclonal antibodies in patients over 65 years, showing similar response rates, reductions in monthly migraine days and adverse effects. Anti-CGRP monoclonal antibodies should likely be offered to patients over 65 although available evidence remains limited. Further studies analyzing specific data from this subgroup are necessary. Migraine in older adults can be more challenging to diagnose and treat due to changes in symptoms and the presence of other health conditions. These factors may limit treatment options. A new class of migraine treatments, called anti-CGRP monoclonal antibodies, has shown promising results in younger patients, but older adults were not included in key clinical trials. This review looks at the available research on how well these treatments work and how safe they are for people over 65. We analyzed studies that included older adults using these medications. The findings suggest that anti-CGRP monoclonal antibodies can reduce migraine frequency and severity in older patients, with effectiveness and side effects similar to those seen in younger adults, showing that they help patients who have not responded to other preventive treatments. However, the number of studies focusing on this age group is still limited. Overall, anti-CGRP monoclonal antibodies appear to be a good treatment option for older adults with migraine, provided they have no conditions that would make the treatment unsafe. However, more research is needed to better understand their long-term effects, particularly in patients with heart and blood vessel conditions, which are more common in this age group.
DOI: 10.6084/m9.figshare.28524231.v1
title: Effectiveness and safety of anti-CGRP monoclonal antibodies for migraine in patients over 65 years: a systematic review

description: Migraine patients over 65 years have been excluded from pivotal anti-CGRP monoclonal antibody trials leaving limited real-life data on effectiveness and safety in this population. This review aims to summarize available evidence on treatment response and safety for older patients. A PubMed and Cochrane Controlled Register of Trials (CENTRAL) search identified studies on anti-CGRP monoclonal antibodies in patients with migraine over 65 up to October 2024. The review focuses on headache outcomes like reduction in monthly migraine days or monthly headache days, response rates (30%, 50%, 75%) and adverse effects of this specific population and/or against placebo, standard care, or younger patients. The quality of evidence was assessed using the GRADE tool. All eligible studies were included, along with additional articles presented narratively. Data from clinical trials and post-hoc analyses show comparable efficacy and safety between older and younger patients. Similarly, early real-life studies support the use of anti-CGRP monoclonal antibodies in patients over 65 years, showing similar response rates, reductions in monthly migraine days and adverse effects. Anti-CGRP monoclonal antibodies should likely be offered to patients over 65 although available evidence remains limited. Further studies analyzing specific data from this subgroup are necessary. Migraine in older adults can be more challenging to diagnose and treat due to changes in symptoms and the presence of other health conditions. These factors may limit treatment options. A new class of migraine treatments, called anti-CGRP monoclonal antibodies, has shown promising results in younger patients, but older adults were not included in key clinical trials. This review looks at the available research on how well these treatments work and how safe they are for people over 65. We analyzed studies that included older adults using these medications. The findings suggest that anti-CGRP monoclonal antibodies can reduce migraine frequency and severity in older patients, with effectiveness and side effects similar to those seen in younger adults, showing that they help patients who have not responded to other preventive treatments. However, the number of studies focusing on this age group is still limited. Overall, anti-CGRP monoclonal antibodies appear to be a good treatment option for older adults with migraine, provided they have no conditions that would make the treatment unsafe. However, more research is needed to better understand their long-term effects, particularly in patients with heart and blood vessel conditions, which are more common in this age group.
DOI: 10.15468/dl.nhhfse
title: Occurrence Download

description: A dataset containing 37 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((16.44736 48.45594,16.66585 48.45594,16.66585 48.56587,16.44736 48.56587,16.44736 48.45594))",
 "HasGeospatialIssue is false",
 "TaxonKey is Orthoptera",
 "Year 2005-2025"
 ]
}

 The dataset includes 37 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009900-250227182430271/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ad286a
title: Occurrence Download

description: A dataset containing 48 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is Asia",
 "Country is China",
 "Geometry POLYGON((-248.48275 28.0046,-243.32039 27.99456,-242.93542 32.12357,-248.21769 32.17747,-248.48275 28.0046))",
 "HasGeospatialIssue is false",
 "Month is one of (January, February, March, April, May, June, July, August, September, October, November, December)",
 "TaxonKey is Mammalia",
 "Year 2024-2024"
 ]
}

 The dataset includes 48 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009901-250227182430271/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.x79z64
title: Occurrence Download

description: A dataset containing 2539 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is Asia",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Ginkgoaceae"
 ]
}

 The dataset includes 2539 records from 105 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009804-250227182400228/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.326gdt
title: Occurrence Download

description: A dataset containing 14800 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Soleirolia soleirolii (Req.) Dandy"
 ]
}

 The dataset includes 14800 records from 252 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009806-250227182400228/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.13145/bacdive5929.20250331.9.3
title: Halococcus dombrowskii Stan-Lotter et al. 2002

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive5929.20251217.10
title: Halococcus dombrowskii Stan-Lotter et al. 2002

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.15156/bio/sh0073968.10fu
title: SH0073968.10FU

description: UNITE provides a unified way for delimiting, identifying, communicating, and working with DNA-based Species Hypotheses (SH). All fungal ITS sequences in the international nucleotide sequence databases are clustered to approximately the species level by applying a set of dynamic distance values (<0.5 - 3.0%). All species hypotheses are given a unique, stable name in the form of a DOI, and their taxonomic and ecological annotations are verified through distributed, web-based third-party annotation efforts. SHs are connected to a taxon name and its classification as far as possible (phylum, class, order, etc.) by taking into account identifications for all sequences in the SH. An automatically or manually designated sequence is chosen to represent each such SH. These sequences are released (https://unite.ut.ee/repository.php) for use by the scientific community in, for example, local sequence similarity searches and next-generation sequencing analysis pipelines. The system and the data are updated automatically as the number of public fungal ITS sequences grows.
DOI: 10.13145/bacdive5930.20250331.9.3
title: Haloferax denitrificans (Tomlinson et al. 1986) Tindall et al. 1989

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.15156/bio/sh0073969.10fu
title: SH0073969.10FU

description: UNITE provides a unified way for delimiting, identifying, communicating, and working with DNA-based Species Hypotheses (SH). All fungal ITS sequences in the international nucleotide sequence databases are clustered to approximately the species level by applying a set of dynamic distance values (<0.5 - 3.0%). All species hypotheses are given a unique, stable name in the form of a DOI, and their taxonomic and ecological annotations are verified through distributed, web-based third-party annotation efforts. SHs are connected to a taxon name and its classification as far as possible (phylum, class, order, etc.) by taking into account identifications for all sequences in the SH. An automatically or manually designated sequence is chosen to represent each such SH. These sequences are released (https://unite.ut.ee/repository.php) for use by the scientific community in, for example, local sequence similarity searches and next-generation sequencing analysis pipelines. The system and the data are updated automatically as the number of public fungal ITS sequences grows.
DOI: 10.13145/bacdive5930.20251217.10
title: Haloferax denitrificans (Tomlinson et al. 1986) Tindall et al. 1989

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive5931.20250331.9.3
title: Haloferax gibbonsii Juez et al. 1986

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.15156/bio/sh0073970.10fu
title: SH0073970.10FU

description: UNITE provides a unified way for delimiting, identifying, communicating, and working with DNA-based Species Hypotheses (SH). All fungal ITS sequences in the international nucleotide sequence databases are clustered to approximately the species level by applying a set of dynamic distance values (<0.5 - 3.0%). All species hypotheses are given a unique, stable name in the form of a DOI, and their taxonomic and ecological annotations are verified through distributed, web-based third-party annotation efforts. SHs are connected to a taxon name and its classification as far as possible (phylum, class, order, etc.) by taking into account identifications for all sequences in the SH. An automatically or manually designated sequence is chosen to represent each such SH. These sequences are released (https://unite.ut.ee/repository.php) for use by the scientific community in, for example, local sequence similarity searches and next-generation sequencing analysis pipelines. The system and the data are updated automatically as the number of public fungal ITS sequences grows.
DOI: 10.13145/bacdive5931.20251217.10
title: Haloferax gibbonsii Juez et al. 1986

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive5932.20250331.9.3
title: Haloferax mediterranei (Rodriguez-Valera et al. 1983) Torreblanca et al. 1987

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.15156/bio/sh0073971.10fu
title: SH0073971.10FU

description: UNITE provides a unified way for delimiting, identifying, communicating, and working with DNA-based Species Hypotheses (SH). All fungal ITS sequences in the international nucleotide sequence databases are clustered to approximately the species level by applying a set of dynamic distance values (<0.5 - 3.0%). All species hypotheses are given a unique, stable name in the form of a DOI, and their taxonomic and ecological annotations are verified through distributed, web-based third-party annotation efforts. SHs are connected to a taxon name and its classification as far as possible (phylum, class, order, etc.) by taking into account identifications for all sequences in the SH. An automatically or manually designated sequence is chosen to represent each such SH. These sequences are released (https://unite.ut.ee/repository.php) for use by the scientific community in, for example, local sequence similarity searches and next-generation sequencing analysis pipelines. The system and the data are updated automatically as the number of public fungal ITS sequences grows.
DOI: 10.13145/bacdive5932.20251217.10
title: Haloferax mediterranei (Rodriguez-Valera et al. 1983) Torreblanca et al. 1987

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive5933.20250331.9.3
title: Haloferax volcanii (Mullakhanbhai and Larsen 1975) Torreblanca et al. 1986

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.15156/bio/sh0073972.10fu
title: SH0073972.10FU

description: UNITE provides a unified way for delimiting, identifying, communicating, and working with DNA-based Species Hypotheses (SH). All fungal ITS sequences in the international nucleotide sequence databases are clustered to approximately the species level by applying a set of dynamic distance values (<0.5 - 3.0%). All species hypotheses are given a unique, stable name in the form of a DOI, and their taxonomic and ecological annotations are verified through distributed, web-based third-party annotation efforts. SHs are connected to a taxon name and its classification as far as possible (phylum, class, order, etc.) by taking into account identifications for all sequences in the SH. An automatically or manually designated sequence is chosen to represent each such SH. These sequences are released (https://unite.ut.ee/repository.php) for use by the scientific community in, for example, local sequence similarity searches and next-generation sequencing analysis pipelines. The system and the data are updated automatically as the number of public fungal ITS sequences grows.
DOI: 10.13145/bacdive5933.20251217.10
title: Haloferax volcanii (Mullakhanbhai and Larsen 1975) Torreblanca et al. 1986

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.15156/bio/sh0073973.10fu
title: SH0073973.10FU

description: UNITE provides a unified way for delimiting, identifying, communicating, and working with DNA-based Species Hypotheses (SH). All fungal ITS sequences in the international nucleotide sequence databases are clustered to approximately the species level by applying a set of dynamic distance values (<0.5 - 3.0%). All species hypotheses are given a unique, stable name in the form of a DOI, and their taxonomic and ecological annotations are verified through distributed, web-based third-party annotation efforts. SHs are connected to a taxon name and its classification as far as possible (phylum, class, order, etc.) by taking into account identifications for all sequences in the SH. An automatically or manually designated sequence is chosen to represent each such SH. These sequences are released (https://unite.ut.ee/repository.php) for use by the scientific community in, for example, local sequence similarity searches and next-generation sequencing analysis pipelines. The system and the data are updated automatically as the number of public fungal ITS sequences grows.
DOI: 10.13145/bacdive5934.20241212.9.2
title: Haloferax volcanii (Mullakhanbhai and Larsen 1975) Torreblanca et al. 1986

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive5934.20251217.10
title: Haloferax volcanii (Mullakhanbhai and Larsen 1975) Torreblanca et al. 1986

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.